机构：[1]Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China[2]Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative Innovation Center of Hematology, Peking University, Beijing, China[3]The first affiliated hospital of Soochow University, Suzhou, China[4]Hematopoietic Stem Cell Transplantation Center, Institute of Hematology and Blood Diseases Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, China[5]Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China[6]Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China南方医科大学珠江医院[7]Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China南方医科大学珠江医院[8]Department of Hematology, First People's Hospital of Chenzhou, Southern Medical University, Chenzhou, China[9]Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
National Natural Science Foundation of China (No. 81600141, No. 81770190) and Natural Science
Foundation of Guangdong Province (No. 2016A030310390): Research Funding.
第一作者机构：[1]Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
推荐引用方式(GB/T 7714)：
Xuan Li,Wang Yu,Chen Jia,et al.Superior Salvage Treatment with Regimen Containing Sorafenib for Relapse of Acute Myeloid Leukemia with FLT3-ITD after Allo-HSCT[J].BLOOD.2018,132:doi:10.1182/blood-2018-99-114103.
APA：
Xuan, Li,Wang, Yu,Chen, Jia,Jiang, Erlie,Gao, Li...&Liu, Qifa.(2018).Superior Salvage Treatment with Regimen Containing Sorafenib for Relapse of Acute Myeloid Leukemia with FLT3-ITD after Allo-HSCT.BLOOD,132,
MLA：
Xuan, Li,et al."Superior Salvage Treatment with Regimen Containing Sorafenib for Relapse of Acute Myeloid Leukemia with FLT3-ITD after Allo-HSCT".BLOOD 132.(2018)
医学